In 2003, we started United BioSource Corporation because we saw unprecedented changes occurring within the health care market that would fundamentally and permanently affect companies that develop and market drugs and devices. We saw increasing government and payor scrutiny of marketing practices. We saw rising fear around the costs of new medications. We witnessed the passage of the Medicare Modernization Act, which legislated the US government into the role of the largest payor for drugs and devices.
In the midst of these disruptive changes, we also saw an industry that was facing increasing challenges bringing new products to market. Research and development budgets were rising precipitously while success rates were shrinking. Since UBC’s founding, none of these issues have diminished. Rather, they have intensified. For developers of drugs and devices to succeed in this environment, we believe that two issues must be met head on:
- Demonstration of real-world evidence to prove that products are efficacious, safe and cost effective not only in randomized, well-controlled trials, but in actual use.
- Demonstration of improved productivity in the Research and Development process, either through methods that increase the probability of success or improve the efficiency of the process.
UBC has been built for this purpose.
We began with an investment $150 million in equity capital provided by leading global investors in health care innovation and technology. Today we have a team of nearly 1,200 professionals in 20 countries dedicated to the specialty services necessary to address these fundamental challenges. We are focused exclusively on those areas where we believe we can make a significant difference and most important, a strategic impact for our clients. Our focus is on utilizing science, innovation and technology to address these challenges.
Our mission is to deliver to our clients unparalleled leadership in the following areas of expertise:
- Design and methodology related to the real world issues of cost effectiveness, health outcomes, drug safety, reimbursement and risk management.
- Design and implementation of programs that ensure data integrity and quality assurance for improved results in randomized clinical trials.
- Development and delivery of productivity software to improve the efficiency and integrity of clinical trials and studies.
- Design and execution of peri- and post-approval global studies capturing real world clinical, safety and health outcomes data.
- Communication of clinical evidence results through software and services that ensure the integrity, transparency and quality of peer-reviewed information.
Our tag line is Evidence Matters. We believe that, ultimately, it is all that matters.
Ethan Leder
CEO